Head-to-head · WeighScore
Harbor vs PlexusDx
By GLP-1 ScorecardUpdated
Score comparison
Harbor has the higher recorded score — 72/100 to 67.7/100.
Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market.
Before you choose
Before comparing the headline prices, the Harbor review and the PlexusDx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Harbor vs Queen RX and NP2GO vs PlexusDx compare each of them with another graded program, and the list of alternatives to Harbor ranks the programs closest to Harbor on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Harbor | PlexusDx |
|---|---|---|
| WeighScore | 72/100 | 67.7/100 |
| Grade | C | C |
| Site position | #94 | #112 |
| Semaglutide | $99/mo (starting dose, compounded) | $99/mo (12-month plan; compounded) |
| Tirzepatide | $149/mo (starting dose, compounded) | $129/mo (12-month plan; compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
- LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
- 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
- 12-Month Money Back Guarantee if you don't reach your weight-loss goal
- HSA/FSA eligible; no hidden fees, no insurance billed
What to consider
- Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
- Dietitian support offered only post-program (maintenance phase), not during active treatment
- State-specific consultation types vary; nationwide availability unconfirmed for all states
- No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
- Newer brand; success rate and member counts are on-site claims, not third-party verified
Strengths
- Licensed providers available in all 50 states
- Range of options including microdose GLP-1 from $69/mo on a 12-month plan
- Optional Precision Peptide genetic panel adds a personalization angle
- Independent clinician review via state-licensed telehealth platform
- Compounded medications from state-licensed pharmacies
What to consider
- Compounded medications only; no FDA-approved brand options
- Specific compounding pharmacies not named
- Genetic-panel upsell may not add clinical value for everyone
- The advertised $99 semaglutide and $129 tirzepatide rates require a 12-month plan; shorter-term prices were not visible
- No insurance accepted
Featured provider
PlexusDx
Factor scores not reassessed.PlexusDx scores 67.7/100 (C). PlexusDx (plexusdx.com) is a US GLP-1 telehealth platform offering compounded weight-loss medications with licensed providers in all 50 states.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.